Department of Health

Bureau of Public Health Laboratories - Tampa

3602 Spectrum Boulevard
Tampa, FL 33612
CLIA: 10D0645546

Service ID: Patient: CARMEN SANTIAGO GONZALES

LIMS Report #: 10514823 1210 RAY CHARLES BLVD
Special Project: Program Component: TAMPA, FL, 33602

Submitter: FDEM University Mall

Local Patient Id: FL000634593
1105 E Kennedy Blvd
Date of Birth: 07/03/1944
Tampa, FL 33602
Social Security #: Gender: Female
Race: Other

Sample #: TVH21017084 (9869229) Date Collected: 04/27/2021

Source: Swab, Oropharyngeal Date Received: 04/27/2021
Sample External ID: Date Reported: 04/27/2021
Order ID: X2100996848 State ID:
Practitioner: DOUGLAS A HOLT Fasting: Pregnant: No
Note: Interested in viewing reports like this one as soon as they become available?

By default, BPHL test reports are sent to the treating physician recorded on the laboratory requisition form
by US Mail. A facility can change their delivery mechanism from US Mail to automatic faxing by following
the instructions at <http://www.floridahealth.gov/programs-and-services/public-health-laboratories/_docu
ments/BPHL_SecureFaxForm_RequestForAutoFaxing.pdf>. After successful completion, the facility will
receive reports automatically to the fax number provided at the time of test report generation in the BPHL
Laboratory Information Management System (LIMS).

To obtain test reports electronically, please request access to the BPHL WebLIMS Portal by following the
instructions at <http://www.floridahealth.gov/programs-and-services/public-health-laboratories/weblims-
ra.html>. Once authenticated as an authorized user, you can view and print all test reports for your
facility as soon as they are generated by logging in at <https://weblims.floridapublichealthlab.com>. Note
that reports can be accessed via WebLIMS in addition to automatic faxing.

Test Result Reference Range Date Approved

9555 2019-Novel Coronavirus RT-PCR Overall SARS-CoV-2 not detected. 04/27/2021

Final
Z_SingleSampleFPH.rpt Page 1 of 2 Print Date: 04/27/2021
 Department of Health
Bureau of Public Health Laboratories - Tampa
3602 Spectrum Boulevard
Tampa, FL 33612
CLIA: 10D0645546

Patient: CARMEN SANTIAGO GONZALES Date of Birth: 07/03/1944 Sample #: TVH21017084 (9869229)

Test Result Reference Range Date Approved

Note: The Aptima SARS-CoV-2 Assay (Panther System) is a nucleic acid amplification in vitro diagnostic test intended for the
qualitative detection of RNA from SARS-CoV-2 isolated and purified from nasopharyngeal (NP), nasal, mid-turbinate and
oropharyngeal (OP) swab specimens, nasopharyngeal wash/ aspirate or nasal aspirates obtained from individuals
meeting COVID-19 clinical and/or epidemiological criteria. The Aptima SARS-CoV-2 Assay is for use only under
Emergency Use Authorization (EUA) in the US laboratories certified under the Clinical Laboratory Improvement
Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests. Results are for the identification of SARS
-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in upper respiratory specimens during the acute phase of
infection. Positive results are indicative of the presence of SARS-CoV-2 RNA, clinical correlation with patient history and
other diagnostic information is necessary to determine patient infection status. Nucleic acid may persist even after the
virus is no longer viable. Positive results do not rule out bacterial infection or co-infection with other viruses. Negative
results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions
. Negative results must be combined with clinical observations, patient history, and epidemiological information.

The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for emergency use of the Aptima
SARS-CoV-2 Assay reported here. Per this authorization, fact sheets for health care providers and patients should be
accessed at <https://www.fda.gov/media/138095/download> and <https://www.fda.gov/media/138098/download>.

Invalid results indicate that there was an error in the generation of the result. The specimen was retested and yielded the
same result. For a result of "Invalid," the provider may consider collecting a new specimen from the patient. Negative test
results from specimens not stored in transport media per the manufacturer instructions, such as stored longer than 72
hours after collection at 2-8°C or not stored at -70°C beyond 72 hours after collection for most types of media, may be
unreliable and the patient may be subject to extra precautions such as additional clinical monitoring, including collection
of an additional specimen.

Final
Z_SingleSampleFPH.rpt Page 2 of 2 Print Date: 04/27/2021